SCHEMBL2467168

SCHEMBL2467168

COc1ccc(COc2ccccn2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.56
RAB9A P51151 1/20 0.56
ALDH1A1 P00352 2/20 0.55
CYP2D6 P10635 2/20 0.55
CYP2C19 P33261 2/20 0.55
APP P05067 5/20 0.50
CNR1 P21554 2/20 0.49
CNR2 P34972 2/20 0.49
MAOB P27338 1/20 0.49
PDE2A O00408 1/20 0.48
ABCB1 P08183 1/20 0.48
IDO1 P14902 2/20 0.47
AGXT P21549 2/20 0.47
LTA4H P09960 1/20 0.47
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
CHRM2 P08172 1/20 0.47
CYP3A4 P08684 1/20 0.47
HTR1A P08908 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29360199 1.00 NPC1 (0.56) NPC1RAB9AALDH1A1CYP2D6CYP2C19
SCHEMBL10055039 0.87 NPC1 (0.68) NPC1RAB9AALDH1A1CYP2D6CYP2C19
SCHEMBL223680 0.81 ALDH1A1 (0.61) NPC1RAB9AALDH1A1CYP2D6CYP2C19
SCHEMBL29816629 0.81 ALDH1A1 (0.61) NPC1RAB9AALDH1A1CYP2D6CYP2C19
SCHEMBL31080534 0.80 NPC1 (0.61) NPC1RAB9AAPPCNR1CNR2
SCHEMBL2176479 0.80 MAOB (0.58) NPC1RAB9AAPPMAOBABCB1
SCHEMBL13513303 0.79 NPC1 (0.55) NPC1ALDH1A1CYP2D6CYP2C19
SCHEMBL21132339 0.79 SYK (0.49) NPC1ALDH1A1CYP2D6CYP2C19LMNA
SCHEMBL510090 0.79 NPC1 (0.63) NPC1RAB9AALDH1A1CYP2D6CYP2C19
SCHEMBL510400 0.79 NPC1 (0.58) NPC1RAB9AALDH1A1CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746871-A2 METHOD OF ENHANCED ABSORPTION OF QUINOXALINE TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ELIXIRON IMMUNOTHERAPEUTICS INC. (TW) 2026-05-27 EP disclosed
WO-2025019622-A2 METHOD OF ENHANCED ABSORPTION OF QUINOXALINE TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ELIXIRON IMMUNOTHERAPEUTICS INC. (TW) 2025-01-23 WO disclosed
CN-115803316-A Pyridone compound and preparation method and application thereof 深圳晶泰科技有限公司 2023-03-14 CN disclosed
CN-105777464-B Hydroxamic acid derivative and preparation method and application thereof 中国科学院上海药物研究所 2020-09-29 CN disclosed
EP-2542077-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS Merck Sharp & Dohme Corp. (US) 2013-01-09 EP disclosed
WO-2011109261-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed
CN-101626686-A 3-substituent-1, 2, 3-benzotriazinone compounds for improving glutaminic synaptic responses CORTEX PHARMA INC 2010-01-13 CN disclosed
US-4728668-A Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments USV PHARMACEUTICAL CORPORATION (US) 1988-03-01 US disclosed
US-4725619-A Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments USV PHARMACEUTICAL CORPORATION (US) 1988-02-16 US disclosed
US-4631287-A Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments USV PHARMACEUTICAL CORP. (US) 1986-12-23 US disclosed
EP-0200101-A2 Aryl and heteroaryl ethers as agents for the treatment of hypersensitive aliments USV PHARMACEUTICAL CORPORATION (US) 1986-11-05 EP disclosed